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Background: Inflammatory bowel diseases (IBD) are a serious burden for both patients and 
health care providers because of the young age at which they occur and their chronic course.
Aim: The purpose of this study was to assess how general practitioners (GPs) in the area of 
Camerino-Matelica, Marche (Central Italy) manage their patients with IBD.
Materials and methods: Before providing an educational course about IBD to GPs, we 
administered a simple questionnaire containing 10 multiple-choice questions, allowing for only 
one possible answer, to GPs in the target area. After the educational course we administered a 
satisfaction questionnaire and evaluated the hospitalization rates for IBD in the catchment area 
in the year following the course.
Results: In our GP sample, 71.8% indicated that they needed better instruction regarding IBD 
to enable them to diagnose the conditions given the difficulties posed by nonspecific symptoms 
and the need to use invasive diagnostic methods such as colonoscopy. Early results after the 
educational course for GPs indicate a reduced rate of hospitalization for IBD but these data 
must be confirmed by future research.
Conclusions: If specialists and GPs managed IBD patients more carefully, their patients 
would probably suffer from fewer relapses and would have a better quality of life, which 
would be likely to mean considerable cost savings for the public health care system and 
society in general.
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Introduction
Inflammatory bowel diseases (IBD) are chronic immune-mediated conditions that are 
associated with a heavy personal and economic burden for patients and health care 
systems. Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main types of 
IBD. Although their etiologies are unknown, some risk factors have been suggested, 
including tobacco use (for CD), genetic factors, oral contraceptives, and hormone 
replacement therapy.1,2
A number of European and US epidemiologic studies indicate a substantial increase 
in the incidence of IBD since World War II, with CD now affecting 6/100,000 and 
UC 15–20/100,000 of the general population.² An Italian multicenter study indicated 
a mean annual incidence of 3.4/100,000 for CD and 7.0/100,000 for UC.3 The preva-
lence of IBD has probably been underestimated, especially in its milder forms.4 The 
Italian Association for IBD Patients (AMICI) has calculated that the total number 
of IBD patients in Italy, as at April 2009, is officially 104,762, with a prevalence of 
177/100,000 in the population but, as reported by Rubin et al, the problem is almost Clinical and Experimental Gastroenterology 2010:3 28
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certainly underestimated given that most studies rely on 
hospital records.5,6
Diagnosis of IBD is often delayed, and the mean interval 
between symptom onset and diagnosis is 1.5–2.0 years. It 
is also difficult to distinguish between CD and UC in clini-
cal practice, because the diagnosis changes within the first 
two years in 10% of patients.7–8 The fact that these diseases 
are difficult to diagnose and demand regular monitoring 
makes the GP’s role fundamental both in establishing the 
primary disease and in dealing with relapses, with a view 
to reducing hospitalizations, and the related problems and 
economic costs. Given the generally young age of IBD 
patients (median age at diagnosis 30 years), the economic 
costs are not limited to hospital stays, treatments, and tests, 
but also include the patient’s decreased ability to work. The 
GP’s role should be borne in mind when looking at all the 
factors (medical and economic) involved in these diseases 
because the GP is the first point of contact for the patient in 
the health care system.9
Rubin et al reported that only 30% of their patients 
were under the care of a specialist, whereas about 50% 
were dispensed from specialist followup. It is noteworthy 
that 48.2% of UC patients and 60.5% of CD patients in this 
study were not on treatment for their disease, and about 
22% of patients with extensive colitis (ie, those most in 
need of cancer screening) were lost to specialist followup.6 
A UK study by Stone et al confirmed Rubin’s findings 
with regard to the prevalence of IBD and showed that 
about 32% of patients were under the care of a GP alone,10 
reporting that only 65% of patients had been prescribed 
5-aminosalicylate in the previous six months, and only 
42% of patients adhered to their prescribed therapy. Also 
noteworthy is that only 69% of CD patients were given 
advice on smoking cessation.
Because 30%–50% of IBD patients are under the care 
of GPs, who as a group do not seem to be well informed 
about the importance of continuous treatment with   
5-aminosalicylate, screening for colon cancer, and the need 
to advise their patients (especially those with CD) to quit 
smoking, we conducted a brief investigation among local 
GPs on relevant topics, including timing of appointments, 
endoscopy, and laboratory followup for IBD patients, and 
hospitalization rates before a continuing medical education 
(CME) course.
Patients and methods
This study was done in a hilly and mountainous area covering 
1281.49 square kilometers in the Marche region of Central 
Italy, inhabited by about 49,100 people (38.2 people per km² 
in December 2005), which is a lower density than the aver-
age for the Marche region (147.9 per km²). There are 39 GPs 
serving the area, comprising 33 males and six females, with 
a mean age of 52.8 ± 4.3 years (median 53 years; range 43–
64 years). Latest data available for this area identify 95 IBD 
patients as at 31 December 2004 (Marche Regional Authority 
database). The prevalence of about 190/100,000 population is 
fairly evenly distributed throughout the Marche region.
In the Marche region about 6.2/100,000 population/year 
are hospitalized for CD (95% confidence interval [CI]: 
6.0–6.4) and 17.7/100,000 for UC (95% CI: 17.6–17.8) 
[database 2004–2006]. In the Camerino-Matelica area, 
13.3/100,000 population/year (95% CI: 12.3–14.2) are admit-
ted to hospital for CD and 23.5/100,000 population/year (95% 
CI: 22.7–24.7) for UC [database 2004–2006]. The above 
reported data are according to statistics from the last ISTAT 
(Italian Statistics Institute) census in 1991.
The mean age of patients hospitalized for IBD in our area 
is similar to the average for the Marche region (45.8 years 
versus 47.1 years, P  0.05), as is the gender distribution 
(55.8% of males in our target area versus 53.3% in whole 
region, P  0.05), so there is unlikely to be any difference 
between the type of patient living in our area and those living 
elsewhere in the Marche region.
In an attempt to improve and coordinate the management 
of these patients, the Department of Surgery in Camerino 
and the Department of Medicine in Matelica instituted 
a CME course for GPs on 25 May 2007. Before starting 
the course, each GP completed an anonymous multiple-
choice questionnaire containing 10 items allowing for 
only one answer to each question (Table 1). The purpose 
of this questionnaire was to assess how GPs approached 
treatment of their IBD patients before they attended the 
course. Following the course, GPs were asked to fill out an 
anonymous questionnaire to assess their satisfaction with 
the course, using a numerical scale of 0–5. We also verified 
the rate of hospitalization of IBD patients in both regional 
(Marche) and local (Camerino-Matelica) hospitals in the year 
following the course.
Statistical analysis
The data were analyzed using the Student’s t-test for mean 
comparisons and the Chi-square test for gender compari-
sons. A P value  0.05 was considered to be statistically 
significant. We used 95% CI for the hospitalization rates. 
The Stata® statistical program, (version 10, Statacorps 
College Station, TX) was used.Clinical and Experimental Gastroenterology 2010:3 29
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Results
Twenty-eight GPs (71.8% of the total canvassed) answered 
the questionnaire and attended the CME course. Only one 
of them had never had an IBD patient. The mean number of 
IBD patients per GP in our catchment area was 2.4. GPs com-
pleted the questionnaire in about five minutes and returned 
their completed questionnaire before starting the course so 
that the information provided on the course could not influ-
ence their subsequent answers.
The GPs visited their patients with the following tim-
ing: monthly 26% of GPs, every three months 33%, every 
six months 30%, and every year 11%. Laboratory tests were 
requested each month by 4% of GPs, every three months 
by 22%, every six months by 59%, and every year by 15%; 
74% of GPs did not require determination of calprotectin in 
patients with IBD and only 15% of GPs used antibiotics in 
CD patients. Also, the use of probiotics in UC was limited, 
with only 37% of GPs always using them (Table 2).
When asked whether they advised female IBD patients 
of child-bearing age to avoid becoming pregnant, 74% of the 
GPs replied “No”. Asked when they requested endoscopic 
followups (excluding patients with cancer), 41% said they 
did so when the disease relapsed, 29% said every two years, 
and 26% said once a year; the other 4% said they did so 
only rarely. Item 8 in Table 1 is basically to double-check of 
Item 7, because variations in therapy often occurred when 
the disease relapsed. The data for Items 7 and 8 in Table 1 
are equivalent.
Results of the satisfaction questionnaire following the 
course indicated that the course was successful in providing 
information to GPs (Table 3). For the following year (2008) 
we verified that regional hospitals had fairly analogous rates 
for CD (6.3/100,000 population/year; 95% CI: 5.1–7.5) and 
for UC (18.9/100,000 population/year; 95% CI: 16.7–21.1) 
to those in the period 2004–2006. Hospitalization rates in the 
Camerino-Matelica area were reduced compared with those 
of previous years but the confidence intervals require confir-
mation (for CD 4.1/100,000 population/year with 95% CI: 
0–9.8 and for UC 10.2/100,000 population/year with 95% 
CI: 1.3–19.1).
Discussion
To the best of our knowledge, the present study is the first in 
Italy to focus on how GPs approach the problem of IBD, and 
it probably reflects the situation in other parts of Central Italy 
too. A weakness of our questionnaire is its generic nature, 
but considering the small numbers of IBD patients followed 
Table 1 GP questionnaire
  1.    Have you ever treated or are you presently treating 
patients with IBD?
  Yes/No
  2.    How often do you examine your IBD patients (not just 
prescribing medicine)?
    Every month, every three months, every six months, or once  
a year.
  3.    How often do you order laboratory tests for your IBD 
patients?
    Every month, every three months, every six months, or once  
a year.
  4.    Do you use the fecal calprotectin test (available at our  
laboratory) for the diagnosis or follow-up of your IBD 
patients?
  Always, almost always, in about half of my patients, rarely.
  5.    Do you prescribe probiotics for your UC patients?
  Always, almost always, in about half of my patients, rarely.
  6.    Do you prescribe antibiotics for your CD patients?
  Always, almost always, in about half of my patients, rarely.
  7.   If your IBD patient relapses, do you involve the specialist?
  Always, almost always, in about half of my patients, rarely.
  8.    If you decide to change your IBD patient’s treatment, do 
you seek advice from a specialist first?
  Always, almost always, in about half of my patients, rarely.
  9.    Do you recommend that your female IBD patients of  
child-bearing age avoid becoming pregnant?
  Yes/No
10.    Apart from patients requiring followup for carcinoma, how 
often do you carry out endoscopic examinations?
  Once a year, once every two years, on disease relapse, rarely.
Table 2 Results of GP questionnaire
   Always  In about 50% 
of cases
Rarely 
Calprotectin analysis 19% 7% 74%
Use of probiotics in UC 37% 41% 22%
Use of antibiotics in CD 15% 41% 44%
Follow-up by specialist in  
relapsed patients
85% 15% 0%
Change of treatment with 
specialist’s advice
85%  15%  0% 
Abbreviations: UC, ulcerative colitis; CD, Crohn’s disease.
Table 3 Results of satisfaction questionnaire
Questions Mean ± SD
How much did the educational course influence  
your knowledge of IBD?
4.2 ± 0.8
How much will the course affect your clinical practice? 3.9 ± 0.9
How interesting did the teachers succeed in making  
the topics covered?
4.0 ± 0.9
Notes: Satisfaction range: 0–5.Clinical and Experimental Gastroenterology 2010:3 30
Sossai et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
up by our GPs (2.4 patients per GP), we opted not to request 
details about specific clinical situations.
Our results indicate that GPs in our area examine their 
IBD patients once every 3–6 months and prescribe labora-
tory tests every six months on average. It is important to 
emphasize that IBD diagnosis and followup must involve 
not just endoscopy but also several laboratory blood and 
fecal tests. Our study indicates that fecal calprotectin, a bio-
chemical marker of inflammatory activity, is still not widely 
used by GPs, and nor are probiotics prescribed for UC, or 
antibiotics prescribed for CD. In addition to being an excel-
lent noninvasive method for monitoring IBD, calprotectin 
is also useful in screening for these diseases.11,12 Fewer 
endoscopies are needed if fecal calprotectin or lactoferrin 
are used to follow up patients, and an endoscopic protocol 
to screen for cancer risk is not needed until 8–10 years after 
the IBD is diagnosed.
Another interesting issue emerging from our study is that 
our group of GPs resort to specialists primarily when their 
patient’s disease relapses, and they tend to adjust therapy 
in consultation with a specialist, probably only when the 
disease relapses. The limited use of probiotics in UC and 
antibiotics in CD by the GPs may in part be due to poor atten-
tion of specialists to these therapies. Williams et al showed 
that both patients and GPs appreciate having ready access 
to the advice of a specialist.13 All the GPs in the Williams 
study were following up at least five IBD patients (twice the 
number that our GPs had in their care), and both patients 
and GPs wanted to be able to contact a specialist easily. It 
is likely that this would apply to our GPs and patients too, 
in the light of responses to Items 7 and 8 in Table 1. Casel-
las et al administered a questionnaire to 393 Spanish IBD 
patients about the services they received and emphasized the 
importance of patients and their families being adequately 
informed about their condition.14 The study was limited by the 
fact that it was conducted in a university environment, but it 
found that 97.8% of the patients considered the information 
they received about their disease inadequate. The authors also 
emphasized that the best way to give patients information 
is by talking to them directly. This is especially important 
because IBD is often associated with depression and anxiety, 
in which case personal contact between patients and their 
health care professionals is essential. Although the number 
of patient hospitalizations and the number of consultations 
with their gastroenterologists do not seem to improve patient 
information flow, we do not know if outpatient contact with 
GPs can improve the level of a patient’s knowledge and 
information about his/her condition.15,16 Undoubtedly, the 
fact that the patients in the present study did not have ready 
access to a psychologist is a severe handicap, resulting in 
patients making more use of the health system’s resources 
and having a suboptimal quality of life.17
Since any given GP has very few IBD patients, it is 
important for them to receive information and training 
periodically from specialists. We believe that the two most 
important duties of a GP are to provide their patients with 
information (also with a view to improving patient adherence 
to prescribed treatments) and to guarantee basic management 
and rapid access to a specialist in the event of relapse.18 Basic 
management should also include monitoring of any adverse 
effects of prescribed drugs. In the case of IBD, underestimat-
ing such adverse effects puts patients at serious risk, not only 
of hematologic sequelae, but also of potential renal, hepatic, 
and pulmonary toxicity.19,20
Although often overlooked, the indirect economic costs 
of a disease are also very important. Stark et al found that the 
monthly cost of an outpatient with CD in Germany is €1425 
and for one with UC it is €1015; 64% of the CD-related 
costs are indirect (eg, sick leave, early retirement) compared 
with 54% for UC patients.21 These costs might increase with 
greater use of biologic therapies, but adequate studies are 
needed, because increasing the use of these treatments might 
mean fewer hospital stays and medical appointments, and 
better quality of life and fewer absences from work.
Another point to emphasize is that our GPs did not advise 
their female IBD patients of child-bearing age to avoid becom-
ing pregnant, even though a recent meta-analysis shows that 
pregnant women with IBD have higher rates of premature 
births, low-birthweight infants, cesarean sections, and babies 
with congenital abnormalities than do non-IBD controls.22 
Although the data available do not permit any correlation of 
such adverse events with the activity of the disease, there are 
sporadic reports of women being more likely to have prema-
ture and low-birthweight infants if they have conceived in an 
active phase of their disease. Important messages that a female 
patient of child-bearing age should receive is that she should 
conceive her child while the disease is quiescent, and that 
close cooperation is needed between her gastroenterologist 
and her obstetrician. The patient needs to be clearly informed 
about which therapies to continue and which to stop, and when 
these should be stopped (ie, during the period of attempting 
to conceive, the first trimester, and lactation).
Perhaps the most interesting finding of this study is that 
the hospitalization rate for IBD was markedly reduced during 
2008 in the Camerino-Matelica area (–69% for CD and –57% 
for UC) while the regional rates remained about the same. Clinical and Experimental Gastroenterology 2010:3
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Of course we cannot exclude the fact that this lower rate was 
compensated for by higher rates in other regional hospitals, 
but we think this improbable, given the information imparted 
to GPs about IBD.
In conclusion, although IBD are not as widespread as 
other chronic diseases, such as hypertension, the fact that the 
incidence of IBD peak in patients about 30 years of age means 
that they can be a heavy burden on the health care system due 
to the patient needing treatment for many years.
We feel that more attention paid to IBD patients by 
GPs would result in cost savings, taking into account the 
balance between the savings (fewer hospital stays, fewer 
days off work) and the added costs (more use of sometimes 
costly medicines, more contact with the specialist). In any 
case, the changes we advocate would certainly result in a 
better quality of life for patients, who would then be able 
to contribute more to their families and communities. It is 
therefore necessary to ensure a good understanding of IBD 
among all health care personnel in order to provide efficient 
service to patients, avoid wasting resources, and improve 
patient quality of life.
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